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Abstract
Background Evidence suggests anthropometric indicators of obesity are associated with changes in sleep quality and quan-
tity, and the presence of obstructive sleep apnoea (OSA). Investigations including diverse and objective evaluations of sleep
and body composition are scarce. We aimed to evaluate the associations between indicators of sleep impairment and body
composition states in a sample from a population-based study.
Methods Participants of the first follow-up of the EPISONO (São Paulo, Brazil) >50 years were cross-sectionally evaluated.
Sleep was assessed through questionnaires, actigraphy, and polysomnography. Body composition was evaluated by bioelectri-
cal impedance analysis. Appendicular skeletal muscle mass adjusted for body mass index defined sarcopenia (men <0.789 and
women<0.512). Total body fat defined obesity (men >30% and women>40%). The overlap between both conditions defined
sarcopenic obesity (SO). Final results were obtained by multinomial logistic regression analysis.
Results Three hundred fifty-nine adults [mean (standard deviation) age, 61 (8.8) years; 212 (59.1%) female] were enrolled.
Obesity was detected in 22.6% of the sample, sarcopenia in 5.6%, and SO in 16.2%. After controlling for covariates, OSA was
associated with SO [odds ratio = 3.14, 95% confidence interval (CI) = 1.49–6.61]. Additionally, nocturnal hypoxaemia was as-
sociated with both obesity (adjusted odds ratio = 2.59, 95% CI = 1.49–4.49) and SO (odds ratio = 2.92, 95% CI = 1.39–6.13).
Other indicators of poor sleep/sleep disorders were not associated with body composition states.
Conclusions Sarcopenic obesity but not obesity alone was associated with OSA. Both obesity and SO but not sarcopenia
were associated with nocturnal hypoxaemia. The findings suggest a complex pathophysiologic relationship between adverse
body composition states and OSA. Upcoming research on risk factors and therapeutic interventions for OSA should target
synchronically the lean and adipose body tissues.
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Introduction
Unfavourable body composition changes develop inexorably
throughout adulthood due to lifelong interactions among
endogenous, environmental, and lifestyle factors.1,2 As a
result, muscle loss and body fat accumulation lead to an
increased risk of sarcopenia and obesity, contributing to
adverse health-related outcomes in advanced ages.3,4 More
recently, the co-presence of sarcopenia and obesity, known
as sarcopenic obesity (SO), has been considered a more dele-
terious body composition phenotype.5 In addition to a myriad
of cardiometabolic outcomes related to the effects of fat
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tissue, higher proportions of fat mass might further
affect muscle quality and increase the risk of disability and
mortality.6 The pathophysiological aspects explaining both
muscle decline and body fat accumulation are multifactorial,
and the mechanisms responsible for these changes are still
under investigation.
Concurrently, sleep parameters worsen during adulthood,
leading to an increased prevalence of sleep disorders from
mid-life to late-life.7 As an example, the majority of older
adults complain of difficulty sleeping, and 36–69% of older
adults report sleep disturbances.8,9 Moreover, respiratory
sleep parameters deteriorate with aging, and a remarkable
age-related increased risk of obstructive sleep apnoea (OSA)
is observed in population-based studies.10–12 OSA has a mul-
tifactorial pathophysiology, and underrecognized risk factors
may play a significant role in the development or worsening
of this condition. Although obesity has a well-established as-
sociation with OSA, more recently, indirect measurements
have suggested that skeletal muscle mass reduction may be
contributing to a higher risk of OSA.13,14
Likewise, other sleep-related measures have been
isolatedly associated with either obesity or sarcopenia in
middle-aged and older adults.15–18 However, no study has
evaluated the associations of sleep with obesity and/or
sarcopenia using simultaneously different sleep assessment
methods and including polysomnography (PSG), the gold-
standard test for the diagnosis of OSA. Furthermore, to our
knowledge, no study examined the potential relationships
of sleep disorders with the co-occurrence of sarcopenia and
obesity (SO). This study aimed to investigate the associations
between sleep features indicating poor sleep/sleep disorder
and different body composition patterns in a sample of
middle-to-old age individuals living in the community.
Materials and methods
Study population
Data from the first follow-up of the Sao Paulo Epidemiologic
Sleep Study (EPISONO) from 2007, comprising a general
population-based sample of Sao Paulo, Brazil, were analysed.
Baseline’s survey design was described in details elsewhere.18
From July 2015 to April 2016, the second wave of this study
was carried out and included 715 individuals of the baseline
sample. Follow-up participants were community-dwelling
adults from both genders and derived from a multi-ethnic
population.
To our particular study analysis, individuals who were
>50 years were included. Pacemaker recipients and those
who were disable and could not undergo the body composi-
tion analysis were excluded from our analysis. Finally, we
used a sample composed of 359 participants (Figure 1). The
Ethical Committee of the Universidade Federal de Sao Paulo
approved this study (registration number 610514/14), which
was conducted according to the ethical standards defined in
the 1964 Declaration of Helsinki as well as its subsequent
amendments and was registered with ClinicalTrials.gov
Figure 1 Project EPISONO flowchart (from the 2007 baseline sample to the 2015 first follow-up) with the exclusion of participants according to
exclusion criteria
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(Identifier NCT00596713). Written informed consent was ob-
tained from all volunteers.
Anthropometry and body composition measures
Height (stadiometer to the nearest 0.1 cm) and weight (elec-
tronic scale to the nearest 0.1 kg) were used to calculate the
body mass index (BMI, kg/m2). Body composition assessment
was performed by a direct segmental multi-frequency bio-
electrical impedance analysis (BIA) using InBody720 (Biospace
Ltd, Seoul, Korea). Eight tactile electrodes (four in contact
with the palm and thumb of hands and four in contact with
the sole of feet) measured the impedance of each body
segment at six different frequencies (1, 5, 50, 250, 500, and
1000 kHz) separately. The measurements were controlled
by a microprocessor, and data output was calculated by a
manufacturer’s algorithm and included total and appendicu-
lar skeletal muscle and fat masses. Previous studies have val-
idated the use of this instrument in different contexts.19–21
Participants were submitted to anthropometric and body
composition measurements right after waking up from an
overnight laboratory-based PSG. They were using light
clothes and fasting for more than 8 h. Voiding was recom-
mended before the BIA.
Skeletal muscle mass index (SMI) for the morphological
criteria definition of sarcopenia was applied according to
the Foundation National Institute of Health, International
Working Group on Sarcopenia.22 More recently, guidelines
have been recommended this criterion as one of the objec-
tive tools for the diagnosis of sarcopenia.23 Appendicular
skeletal muscle mass adjusted for BMI was generated for
each participant, and pre-specified cut-offs for sarcopenia
were established according to previous studies (men:
<0.789 and women: <0.512).23 Obesity was defined as total
body fat >30% (men) and >40% (women).24 SO was deter-
mined by the overlap between both definitions.
Sleep measures and definitions
During sleep evaluation, participants completed the Pittsburgh
Sleep Quality Index (PSQI), which subjectively measures the
sleep quality over a 1month period. Global PSQI scoring ranges
from 0 to 21. Scores >5 are considered as poor self-reported
sleep quality and have a sensitivity of 89.6% and specificity of
86.5% in distinguishing good vs. poor sleepers.25 The Epworth
Sleepiness Scale, a questionnaire that classifies subjective
daytime sleepiness, scoring from 0 to 24, with a score of >10
indicating excessive daytime sleepiness, was also completed.26
A subjective sleep assessment using the ‘Universidade Federal
de São Paulo (UNIFESP)’ Sleep Questionnaire additionally
included questions related to insomnia symptoms.19 Chronic
insomnia complaint was defined as the report of regular
insomnia symptoms (difficulties initiating/maintaining sleep
and early morning awakenings, occurring at least three times
a week, during at least 3 months).27
Nocturnal average sleep duration was objectively evalu-
ated by actigraphy (Motionlogger Watch, Ambulatory Moni-
toring Inc., EUA). Volunteers were invited to use the device
for 10 consecutive days. Similar to a wristwatch device mon-
itoring, the actigraph was used in the non-dominant arm for
at least three consecutive days for the assessment of the
sleep–wake patterns. Collected data applied the zero-crossing
mode, in 1 min epochs.28 A sleep diary was filled out during
this period to obtain information related to sleep and activity.
A validated algorithm estimated the sleep-related variables.29
Objective short sleep duration was defined as averaged
nocturnal sleep duration measured by actigraphy <6 hr.
The median registry of actigraphy data was nine 24 h periods
[interquartile range (IQR), 4–10).
Additional objective sleep parameters were measured by
an overnight laboratory-based PSG study, including sleep la-
tency, sleep efficiency, wake time after sleep onset, sleep
stages 3 (N3, %) and rapid eye movement (REM, %), periodic
limb movement index (events/h), apnoea–hypopnoea index
(AHI, events/h), and nocturnal hypoxaemia, defined as the
per cent of time during sleep with percutaneous oxygen sat-
uration (SpO2) <90% (% of total sleep time with SpO2 <90%).
Sleep recording was performed by PSG technologist using a
digital system (EMBLA® N7000, Embla Systems Inc., Broom-
field, CO, USA). The following physiological tests were
conducted: electroencephalography (EEG; F3-M2, F4-M1,
C3-M2, C4-M1, O1-M2, and O2-M1), electrooculography
(EOG; EOG-Left-M2 and EOG-Right-M1), electromyography
(muscle of the submentonian region, tibialis anterior muscle,
masseter, and temporal region), electrocardiography (deriva-
tion D2 modified), and airflow detection by both thermocou-
ple and nasal cannula. Respiratory effort was assessed by
inductance plethysmography belts. Snoring, body position,
SpO2, and pulse rate were evaluated by EMBLA
® sensors
(Embla Systems Inc., Broomfield, CO, USA). All PSGs were per-
formed and scored by two technicians following guidelines
for sleep studies and were reviewed by a sleep medicine
physician. Sleep stages, EEG arousals, and leg movements
were scored according to established criteria.30
Apnoea was defined as complete or close to complete air-
flow cessation for ≥10 s, and hypopnoea was identified as an
evident reduction in the breathing amplitude (at least 30%
below the baseline) for ≥10 s accompanied by either an EEG
arousal or a SpO2 drop ≥3%. OSA was defined according to
AHI >15.31,32
Covariates
During the interview at the sleep laboratory, the application
of the Socio-economics and Demographics Questionnaire
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obtained general characteristics including age, gender, ethnic-
ity (African–Americans, Caucasians, and others),33 education
level (college/graduate vs. lower education level), marital sta-
tus (married/living together vs. single/divorced/widowed), so-
cial classification (high vs. lower level), smoking status (never,
past, and current), alcohol intake (categorized into days per
week of consumption: 0, 1–2, or ≥3), and recommended
physical activity/week (>150 min of moderate-intensity exer-
cise and/or 75 min of high-intensity exercise vs. lower exer-
cise levels).33,34 Participants were considered to have clinical
comorbidity if they reported a previous physician diagnosis
of one of the following: hypertension, diabetes, chronic
osteoarticular disease, chronic pulmonary disease, cardiovas-
cular diseases, and heart failure. The number of clinical co-
morbidities was categorized into a comorbidity index: 0, 1,
or ≥2. The total score in the Beck Depression Inventory eval-
uated depression symptoms.35 All current medications (pre-
scription, over-the-counter, or vitamins) were registered and
categorized according to their pharmacological class.
On the morning following the PSG exam, participants had a
blood sample collected (12 h of fasting) for quantification of
serum biochemical levels including total 25-hydroxyvitamin
D (25(OH)D), insulin-growth factor 1 (IGF-1), free testoster-
one, leptin, adiponectin, interleukin 6 (IL-6), interleukin 10
(IL-10), tumour necrosis factor-alpha (TNF-α), and ferritin,
which was quantified using standardized laboratory assay
procedures described previously in detail.19
Statistical analyses
Characteristics of participants were described using means
and standard deviations or counts and percentages. Skewed
variables were summarized using medians and IQRs. One-
way ANOVA or Kruskal–Wallis and χ2 tests of homogeneity
or Fisher’s exact test were used when appropriate to com-
pare participants’ characteristics according to body composi-
tion definitions (normal, obesity, sarcopenia, and SO).
Univariate analysis also compared normal and different ad-
verse body composition patterns according to sleep features
indicating poor sleep or sleep disorders: poor subjective sleep
quality in the last month (PSQI >5 vs. <5),25 excessive day-
time sleepiness (Epworth Sleepiness Scale >10 vs. <10),26
chronic insomnia complaint,27 objectively measured short
sleep duration (average nocturnal sleep duration from
actigraphy <6 h),36,37 prolonged sleep latency (>30 min vs.
<30 min),38 reduced sleep efficiency (<80% vs. >80%),38
increased night-time wakefulness (wake time after sleep
onset >60 min vs. <60 min),39 reduced N3 sleep (% N3 sleep
stage 1st vs. 4th quartile),38 reduced REM sleep (% REM sleep
stage 1st vs. 4th quartile),38 periodic limb movements of
sleep (periodic limb movement index >15 vs.<15),40 OSA ac-
cording to AHI (AHI >15 vs. <15),41 and nocturnal hypoxia
(>1% of sleep time with SpO2 <90% vs. <1%).
38 Only sleep
variables that were significantly associated with body
composition status in the univariate analysis were considered
to the subsequent multivariate modelling strategy.
Multinomial logistic regression models were applied to
analyse the possible associations between each sleep variable
as a main predictor and body composition categorized as ad-
verse body composition patterns as the outcome (obesity,
sarcopenia, and SO), using normal body composition category
as the reference. Results were presented as adjusted odds ra-
tio and 95% confidence interval (CI). For each one of the final
multiple regression models including one of the sleep vari-
ables, known or suspected determinants of sleep predictors
and body composition outcomes were examined for potential
confounding. After evaluation according to biological plausi-
bility, covariates in age and gender-adjusted models with
P < 0.20 were considered for inclusion in the full multivariate
models. Potential confounders tested for inclusion were
ethnic group, social class, education, marital status, smoking
status, alcohol consumption, recommended physical activity
per week, number of comorbidities, Beck Depression Inven-
tory score, psychotropic/hypnotic use, diuretic use,
angiotensin-converting enzyme inhibitors/angiotensin recep-
tor blockers use, serum measures of 25(OH)D, IGF-1, free tes-
tosterone (gender-specific lower tertile), leptin, adiponectin,
IL-6, IL-10, TNF-α, and ferritin. Before the covariate selection
process, serum measures of 25(OH)D, IGF-1, free testoster-
one, leptin, adiponectin, IL-6, IL-10, TNF-α, and ferritin were
examined as potential mediators using the Sobel–Goodman
test followed by bootstrap with case resampling.
Because measures of sleep duration averaged over five
nights of actigraphy recording were more likely representa-
tive of usual sleep duration pattern than only three nights,
a sensitivity analysis excluding participants with <5 days of
actigraphy registration was performed. As results were not
significantly different after this exclusion, only results for
the total sample were presented. Similarly, as a sensitivity
analysis excluding eight participants with central sleep ap-
noea (central apnoea events >50% of total AHI >15) also
did not affect the results, the entire sample was considered
when testing the effects of OSA. All analyses were performed
using STATA software, version 14.2 (Stata Corp., College
Station, Texas, USA), and a P value <0.05 was considered
statistically significant.
Results
General characteristics associated with adverse body compo-
sition patterns
Among the 359 participants [212 (59.1%) women], 164
(45.68%) were 60 years or more. Table 1 shows sample distri-
butions according to body composition classification, from
which 200 (55.71%) were classified as normal regarding SMI
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and total fat mass, 20 (5.57%) were classified as sarcopenic,
81 (22.56%) were classified as obese, and 58 (16.16%) were
considered SO. No significant differences were observed
among the four categories according to ethnicity, marital sta-
tus, social classification, smoking status, alcohol intake, rec-
ommended levels of physical activity, Beck Depression
Inventory score, psychotropic/hypnotic use, 25(OH)D, free
testosterone, adiponectin, IL-6, IL-10, TNF-α, and ferritin.
Age was higher among those with sarcopenia and SO. Con-
trasting with other body composition states, obesity status
tended to be more observed in women. Sarcopenia and SO
were less observed in people with higher education. Partici-
pants classified as normal tended to have a lower number
of comorbidities. Diuretic use was more observed among
those with SO. Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker use was more frequent among
those with obesity and SO. IGF-1 was lower and leptin was
higher among those with obesity and SO.
Indicators of poor sleep and sleep disorders
associated with body composition states
Univariate associations between poor sleep indicators/sleep
disorders and body composition states are displayed in Table
2. Increased night-time wakefulness, reduced REM sleep,
OSA, and nocturnal hypoxaemia were significantly different
among the body composition categories. A higher proportion
of SO participants had increased night-time wakefulness.
Among those with a normal body composition state, a lower
proportion had reduced REM sleep. OSA was more observed
in participants with SO, and nocturnal hypoxaemia was more
frequent in those with obesity and SO.
Table 3 shows the selected indicators of poor sleep/sleep
disorder as potential main predictors of adverse body compo-
sition states after multivariate analyses. After controlling for
age and gender, OSA and nocturnal hypoxaemia were associ-
ated with an increased likelihood of obesity. OSA and
nocturnal hypoxaemia were associated with SO. In the final
multivariate models, OSA continued to be associated only
with SO (OR = 3.14, 95% CI = 1.49–6.61) (Figure 2). Moreover,
nocturnal hypoxaemia continued to be significantly
associated with obesity (adjusted odds ratio = 2.59, 95%
CI = 1.49–4.49) and SO (OR = 2.92, 95% CI = 1.39–6.13). None
of the poor sleep indicators and sleep disorders was associ-
ated with sarcopenia.
Discussion
This study extensively explored the associations of sleep fea-
tures derived from subjective and objective methodological
sources with unfavourable body composition states in a
sample of adults >50 years. After multiple confounding
adjustments, OSA was only significantly associated with SO.
Moreover, nocturnal hypoxaemia was associated with both
obesity and SO. The final analysis did not find indicators of
poor sleep/sleep disorders associated with sarcopenia
exclusively. As far as we know, this is the first study to dem-
onstrate the significant association between objective sleep
parameters of OSA and SO in adults from the community.
Table 2 Poor sleep indicators and sleep disorders according to body composition status
Overall sample Normal Obese Sarcopenic Sarcopenic obese P valuea
Poor subjective sleep quality in the last
month (PSQI score >5)—n (%)
179 (49.86) 98 (49.00) 40 (49.38) 10 (50.00) 31 (53.45) 0.95
Chronic insomnia complaint
(>3 times/week; >3 months)—n (%)
211 (58.77) 109 (54.50) 54 (66.67) 12 (60.00) 36 (62.07) 0.28
Excessive daytime sleepiness
(ESS score >10)—n (%)
127 (35.38) 75 (37.50) 31 (38.27) 7 (35.00) 14 (24.14) 0.27
Objective short sleep duration—n (%)b 74 (20.61) 38 (19.00) 18 (22.22) 4 (20.00) 14 (24.14) 0.83
Prolonged sleep latency (>30 min)—n (%) 47 (13.24) 21 (10.55) 14 (17.72) 2 (10.00) 10 (17.54) 0.29
Reduced sleep efficiency (<80%)—n (%) 173 (48.73) 93 (46.73) 33 (41.77) 14 (70.00) 33 (57.89) 0.06
Increased night-time wakefulness
(>60 min)—n (%)
219 (61.69) 117 (58.79) 44 (55.70) 16 (80.00) 42 (73.68)d 0.04
Reduced N3 sleep (%) (1st quartile)—n (%)c 96 (27.04) 66 (33.17) 14 (17.72) 8 (40.00) 12 (21.05) 0.06
Reduced REM sleep (%) (1st quartile)—n (%)c 126 (35.49) 58 (29.15)d 34 (43.04) 10 (50.00) 24 (42.11) 0.03
PLM (>15 events/h)—n (%) 57 (15.88) 25 (12.50) 20 (24.69) 4 (20.00) 8 (13.79) 0.08
Obstructive sleep apnoea (AHI > 15)—n (%) 186 (52.39) 86 (43.22)d 46 (58.23) 13 (65.00) 41 (71.93)d <0.0001
Nocturnal hypoxaemia (>1% of TST
with SaO2 <90%)—n (%)
168 (47.32) 71 (35.68)d 52 (65.82)d 7 (35.00) 38 (66.67)d <0.0001
AHI, apnoea–hypopnoea index; ESS, Epworth Sleepiness Scale; N3, sleep stage 3; PLM, periodic limb movements of sleep; PSQI, Pittsburg
Sleep Quality Index; REM, rapid eye movements; TST, total sleep time during polysomnography.
P value <0.05 was considered statistically significant.
aDifferences according to body composition status in univariate analysis.
bNocturnal average sleep duration <6 h measured by actigraphy.
c4th quartile as a reference.
dBody composition categories that were considered significantly different.
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Other indicators of poor sleep, such as poor sleep quality, ob-
jective short sleep duration, reduced sleep efficiency, and in-
creased night-time wakefulness were not associated with
sarcopenia, obesity, or SO.
OSA is frequent among adults in all age groups. Previous
studies found prevalence rounding 10%, although more re-
cent population-based studies using updated measurement
techniques and recommended criteria observed higher
frequencies, achieving more than 30%.10,42 Accordingly, using
data from the follow-up of the EPISONO, 34.4% of partici-
pants in our sample had moderate-to-severe OSA. Addition-
ally, aging is one of the most critical risk factors for OSA.9 In
our study, 186 (52.4%) participants (>50 years) had the diag-
nosis of OSA. This sleep disorder is related to a variety of
health-related consequences across all age groups, including
increased risk of cognitive impairment, depression, metabolic
disorders, hypertension, cardiovascular disease, atrial fibrilla-
tion, and mortality.43–45 Possibly, these outcomes might be in
part explained by the association between OSA and SO.
In fact, disproportions between an excessive amount of fat
mass relative to a reduced lean mass and a severe increase in
the AHI are related to disruptions in inflammatory and meta-
bolic pathways.46,47 Pro-inflammatory cytokines, such as IL-6
and TNF-α, are both increased in people with SO and
OSA.48,49 Similarly, adverse hormonal profiles involving leptin,
adiponectin, IGF-1, and testosterone, as well as increased in-
sulin resistance, are commonly described in pathophysiologi-
cal models explaining both SO and OSA.6,50–52 For instance,
our analyses showed IGF-1 levels tended to be lower among
OSA participants and SO participants. Moreover, mediation
analysis revealed IGF-1 as a potential mediator of the associ-
ation between OSA and SO (data not shown). Indeed, OSA
negatively impacts the growth hormone/IGF-1 axis among
obese subjects.53–55 The degree to which these analogies
are related to our findings needs further research exploring
potential common mechanisms between both conditions.
Participants with SO tended to have a higher frequency
(71.9%) of OSA than those with obesity (58.2%) or
sarcopenia (65.0%) alone. Previous literature has shown that
OSA leads to a higher risk of adverse clinical consequences
affecting multiple organ systems, including cardiometabolic
comorbidities and mortality.56 SO but not sarcopenia or obe-
sity alone was associated with OSA in our study. Indeed,
body fat accumulation adjacent to the neck may mechani-
cally promote upper airway obstruction during sleep.57 Like-
wise, central obesity diminishes lung capacity and alters
airflow dynamics, increasing pharyngeal resistance.58 Al-
though these adiposity-related mechanisms are increasingly
well-established factors related to the development of OSA,
our data may further suggest that they might be insufficient
to the development of established OSA states in people
around old age.
Hence, not only fat mass gain but also skeletal muscle mass
reduction may play a role in the pathophysiology of OSA. In a
20–30 years follow-up study, evidence of increased AHI was
detected in community-dwelling middle-aged and elderly
individuals after a significant decrease or maintenance in
body weight, suggesting muscle decline might be related to
apnoea occurrence.13 Previous data indicated that airway
anatomy/collapsibility has a greater pathogenic effect on
the development of OSA as people age.14 In contrasting this
evidence with our results, it is possible to hypothesize that
both the accumulation of fat tissue around the airway and
the loss of pharyngeal/laryngeal muscle mass may explain
the association of OSA with SO. The potential synergistic role
of both obesity and sarcopenia characteristics in the mecha-
nisms of OSA might endorse previous studies suggesting SO
as a more harmful body composition phenotype.59 Further
prospective research looking at the morphologic and
functional mechanisms of sarcopenia and SO in the airway
collapsibility are required to confirm the relevance of muscle
deterioration on the pathophysiology of OSA.
Figure 2 Multivariate adjusted odds ratios for adverse body composition states by OSA status
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Among our findings, nocturnal hypoxaemia was associated
with both obesity and SO. Obesity hypoventilation syndrome
(OHS) is a sleep-related hypoventilatory condition frequently
observed in obese subjects but with a disproportionate
greater morbimortality in comparison with obesity alone.27,60
Resting daytime hypercapnia is also recommended for the
OHS diagnosis. In our study, although this criterion was not
evaluated, the absence of an alternative cause for alveolar
hypoventilation allows us to consider OHS as a possible cause
for nocturnal hypoxaemia in individuals with obesity or SO, as
results were controlled for potential differential diagnoses
including pulmonary diseases. The pathophysiology of OHS
remains not entirely characterized.61 Restrictive lung physiol-
ogy promoted by fat accumulation seems to be a mechanistic
key factor for the development of OHS, resulting in breathing
overload, oxygen consumption, and CO2 production.
62
Moreover, leptin resistance appears to affect the ventila-
tory control.63 Accordingly, our analysis resulted in significant
higher median leptin levels among those with obesity or SO,
as well as in those with nocturnal hypoxaemia (data not
shown). The similar associations of nocturnal hypoxaemia
with both obesity and SO and the lack of association with
sarcopenia suggest a preponderant role of fat deposition over
the lean mass decline in the pathophysiology of the OHS. In
fact, the potential role of muscle deterioration on respiratory
dynamics remains elusive, even in chronic obstructive pulmo-
nary disease patients.64 On the other hand, some authors
have suggested that hypoxia might negatively impact muscle
mass and increase the risk of sarcopenia.65,66 Therefore, fu-
ture prospective studies focusing on the effects of nocturnal
hypoxaemia on body composition and muscle function may
elucidate the potential bidirectional relationships between
nocturnal hypoxaemia and muscle deterioration.
Sarcopenia was not associated with indicators of poor
sleep in our study. Otherwise, a few recent studies have sug-
gested possible relationships between sleep and sarcopenia.
A cross-sectional study evaluating 488 older adults found that
subjectively assessed short sleep duration (<6 h) was associ-
ated with sarcopenia defined by BIA.16 In contrast, our results
did not find significant associations between objective-sleep
duration and adverse body composition patterns. Differences
in the study population, assessment methods, or even in the
statistical analysis approach may justify this divergence. Nev-
ertheless, additional studies are required to explore the rela-
tionship between more precise measurements of sleep
duration and sarcopenia.
Another study including community-dwelling very old
adults (>80 years) and applying actigraphy measures found
that higher bedtime variability (a measure of sleep pattern
variation) was independently related to reduced lean mass
and increased fat mass.17 Circadian rhythm disruptions are in-
creasingly frequent with aging and can impact body composi-
tion negatively.67 Our study included participants with a
broader age range, and indicators of night-to-night sleep
variability were not explored. Further research is also ex-
pected to investigate the role of different sleep pattern mea-
sures in the development of unfavourable body composition
states across distinct age groups.
In contrast to our findings, a more recent epidemiological
study showed that subjective-measured poor sleep quality
(PSQI total score >5) was associated with sarcopenia in
middle-aged adults.18 More than 90% of participants were
Caucasians, and older adults were not included. In contrast,
our sample comprised a multi-ethnic and older group, with
57.9% of Caucasians and nearly 50% of aged persons. Our
lower sample size did not allow us to perform subgroup anal-
yses according to age group and ethnicity. Moreover, a
greater number and diversity of potential confounders in-
cluded in our final analysis might also explain the absence of
subjective sleep quality effects on body composition states.
This study has some limitations. Among them, the cross-
sectional design does not allow any conclusion towards a
causal explanation for the findings. Although a large number
of well-selected confounders included in the analysis reduced
the risk of residual or unmeasured confounding effect, die-
tary pattern, which can impact on body composition, was
not evaluated. Due to sample size limitations, we could not
perform subgroup analysis regarding age-specific or gender-
specific differences in the results. Moreover, low statistical
power may explain the absence of some potential associa-
tions between sarcopenia and indicators of poor sleep or
sleep disorders, as few participants were classified as
sarcopenic. Although most of the sleep indicators were pro-
vided by objective measurement methods, they do not nec-
essarily reflect the sleep pattern of participants. Sleep
assessments were performed respecting habitual bedtimes,
but the single night PSG recording might lead to a lack of ha-
bituation to this method. On the other hand, sleep duration,
one of the variables that best reflects sleep pattern,
expressed the mean sleep time during nine nights of
actigraphy registry on average, generating a more reliable re-
port of participant’s sleep quantity.
Body composition was assessed by BIA (Inbody720,
Biospace Ltd. Seoul, Korea), which has shown excellent agree-
ment with the gold-standard dual-energy X-ray absorptiome-
try.22 Although overestimations in the body composition
measures are still a concern when using BIA, time and cost ef-
ficiency, as well as the lack of X-ray exposure of this modern
BIA technique, offered a more favourable option to body
composition analysis in a population-based study. Although
sarcopenia and SO include decreased muscle mass as re-
quired diagnostic criteria, the majority of updated recom-
mendations emphasize the importance of muscle function
evaluations for supporting these diagnostics.40,68 Despite
the absence of performance measurements, our study ap-
plied validated cut-points and recommended diagnostic
criteria for reduced lean mass that were previously able to
predict significant weakness using a pooled sample originated
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from nine different longitudinal cohorts or clinical trial stud-
ies.23 Moreover, the relevance of our findings relies on the
originality of revealing potential relationships between sleep
and sarcopenia or SO, which are expected to be further ex-
plored in upcoming investigations.
Conclusions
The objective of this study was to investigate the possible as-
sociations between indicators of poor sleep/sleep disorders,
focusing on OSA, and a broader number of adverse body
composition phenotypes, including obesity, sarcopenia, and
SO. Finally, the findings showed that OSA is associated with
SO, and nocturnal hypoxia is associated with both obesity
and SO. The growing coexistence of OSA and SO may further
aggravate the consequences of each one of them isolatedly.
Also, the intertwined pathophysiological mechanisms shared
by OSA and SO are potential targets for future interventions
aiming to reduce morbimortality in those suffering from
these disorders. Upcoming prospective studies and clinical tri-
als are expected to advance the elucidation of these findings.
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